CA2257751C - An intravascular stent having an improved strut configuration - Google Patents
An intravascular stent having an improved strut configuration Download PDFInfo
- Publication number
- CA2257751C CA2257751C CA002257751A CA2257751A CA2257751C CA 2257751 C CA2257751 C CA 2257751C CA 002257751 A CA002257751 A CA 002257751A CA 2257751 A CA2257751 A CA 2257751A CA 2257751 C CA2257751 C CA 2257751C
- Authority
- CA
- Canada
- Prior art keywords
- stent
- struts
- bridges
- loops
- vessel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000003780 insertion Methods 0.000 claims abstract description 11
- 230000037431 insertion Effects 0.000 claims abstract description 11
- 229910045601 alloy Inorganic materials 0.000 claims description 19
- 239000000956 alloy Substances 0.000 claims description 19
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 8
- 229910052759 nickel Inorganic materials 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 2
- 239000010936 titanium Substances 0.000 claims 2
- 229910052719 titanium Inorganic materials 0.000 claims 2
- 229910000734 martensite Inorganic materials 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 229910001566 austenite Inorganic materials 0.000 description 16
- 230000009466 transformation Effects 0.000 description 14
- 229910052751 metal Inorganic materials 0.000 description 13
- 239000002184 metal Substances 0.000 description 13
- 238000005452 bending Methods 0.000 description 8
- 239000010410 layer Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000010935 stainless steel Substances 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 5
- 230000003073 embolic effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000001788 irregular Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- KHYBPSFKEHXSLX-UHFFFAOYSA-N iminotitanium Chemical compound [Ti]=N KHYBPSFKEHXSLX-UHFFFAOYSA-N 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000013047 polymeric layer Substances 0.000 description 2
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229920006099 Vestamid® Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- RZDQHXVLPYMFLM-UHFFFAOYSA-N gold tantalum Chemical compound [Ta].[Ta].[Ta].[Au] RZDQHXVLPYMFLM-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91558—Adjacent bands being connected to each other connected peak to peak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0028—Shapes in the form of latin or greek characters
- A61F2230/005—Rosette-shaped, e.g. star-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0028—Shapes in the form of latin or greek characters
- A61F2230/0054—V-shaped
Abstract
In accordance with the present invention, there is provided a stent for insertion into a vessel of a patient the stent is a tubular member with a predetermined a thickness. The member has front and back open ends and a longitudinal axis extending therebetween.
The stent has a first smaller diameter for insertion into the vessel, and a second larger diameter for deployment into the vessel. The tubular member includes a plurality of adjacent hoops extending between the front and back ends. The hoops are made from a plurality of longitudinal struts and a plurality of loops connecting adjacent struts. The member further includes a plurality of bridges connecting adjacent hoops to one another. The individual struts have lengths, as measured parallel to the longitudinal axis. The stent is constructed so that the ratio of the number of struts per hoop to the length of a strut, as measured in inches, is greater than about 400.
The stent has a first smaller diameter for insertion into the vessel, and a second larger diameter for deployment into the vessel. The tubular member includes a plurality of adjacent hoops extending between the front and back ends. The hoops are made from a plurality of longitudinal struts and a plurality of loops connecting adjacent struts. The member further includes a plurality of bridges connecting adjacent hoops to one another. The individual struts have lengths, as measured parallel to the longitudinal axis. The stent is constructed so that the ratio of the number of struts per hoop to the length of a strut, as measured in inches, is greater than about 400.
Description
AN INTRAVASCULAR STENT HAVING AN
IMPROVED STRUT CONFIGURATION
Mark Mathis Thomas Duerig FIELD OF THE 1)WENTION
The present invention relates to an expandable intraluminal grafts ("stents") for use within a body passageway or duct which are particularly useful for repairing blood vessels narrowed or to occluded by disease. The present invention relates even further to such stents which are self expanding and made from a superelastic material such as Nitinol. The present invention also relates to delivery systems for such stents.
BACKGROUND OF THE INVENTION
15 Percutaneous transluminal coronary angioplasty (PTCA) is a therapeutic medical procedure used to increase blood flow through the coronary artery and can often be used as an alternative to coronary by-pass surgery. In this procedure, the angioplasty balloon is inflated within the stenosed vessel, or body passageway, in order to shear and disrupt the wall components of the vessel to obtain an enlarged lumen. With respect to arterial stenosed lesions, 2o the relatively incompressible plaque remains unaltered, while the more elastic medial and adventitial layers of the body passageway stretch around the plaque. This process produces dissection, or a splitting and tearing, of the body passageway wall layers, wherein the i~ima, or internal surface of the artery or body passageway, suffers fissuring. This dissection forms a "flap"
of underlying tissue which may reduce the blood flow through the lumen, or block the lumen.
25 Typically, the distending intraluminal pressure within the body passageway can hold the disrupted layer, or flap, in place. If the intimal flap created by the balloon dilation procedure is not maintained in place against the expanded intima, the intimal flap can fold down into the hunen and close off the lumen, or may even become detached and enter the body passageway. When the intimal flap closes off the body passageway, immediate surgery is necessary to correct this 3o problem.
/v 'D~ - 7 Recently, transluminal prostheses have been widely used in the medical arts for implantation in blood vessels, biliary ducts, or other similar organs of the living body. These prostheses are commonly known as scents and are used to maintain, open, or dilate tubular structures. An example of a commonly used stent is given in U.S. Patent 4,733,665 filed by Palmaz on November 7, 1985, which is hereby incorporated herein by reference.
Such stents are often referred to as balloon expandable stents. Typically the stent is made from a solid tube of stainless steel. Thereafter, a series of cuts are made in the wall of the stent. The stent has a first smaller diameter which permits the stmt to be delivered through the human vasculature by being crimped onto a balloon catheter. The stent also has a second, expanded diameter, upon the 1o application, by the balloon catheter, from the interior of the tubular shaped member of a radially, outwardly extending.
However, such stents are often impractical for use in some vessels such as the carotid artery. The carotid artery is easily accessible from the exterior of the human body, and is often visible by looking at ones neck. A patient having a balloon expandable stent made from stainless 1s steel or the like, placed in their carotid artery might be susceptible to sever injury through day to day activity. A sufficient force placed on the patients neck, such as by falling, could cause the stent to collapse, resulting in injury to the patient. In order to prevent this, self expanding stents have been proposed for use in such vessels. Self expanding stents act like springs and will recover to their expanded or implanted configuration after being crushed.
2o One type of self-expanding stent is disclosed in U.S. Patent 4,665,771, which stent has a radially and axially flexible, elastic tubular body with a predetermined diameter that is variable under axial movement of ends of the body relative to each other and which is composed of a plurality of individually rigid but flexible and elastic thread elements defining a radially self expanding helix. This type of stent is known in the art as a "braided stent"
and is so designated 2s herein. Placement of such stents in a body vessel can be achieved by a device which comprise an outer catheter for holding the stent at its distal end, and an inner piston which pushes the stent forward once it is in position.
However, braided stents have many disadvantages. They typically do not have the necessary radial strength to effectively hold open a diseased vessel. In addition, the plurality of 3o wires or fibers used to make such stents could become dangerous if separated from the body of the stent, where it could pierce through the vessel. Therefore, there has been a desire to have a self expanding stent, which is cut from a tube of metal, which is the common manufacturing method for many commercially available balloon expandable stents. In order to manufacture a self-expanding stent cut from a tube, the alloy used would preferably be superelastic or psuedoelastic characteristics at body temperature, so that it is crush recoverable.
The prior art makes reference to the use of alloys such as Nitinol (Ni-Ti alloy) which have shape memory and/or superdastic characteristics in medical devices which are designed to be inserted into a patient's body. The shape memory characteristics allow the devices to be deformed to facilitate their insertion iMo a body lumen or cavity and then be heated within the body so that 1o the device returns to its original shape. Superelastic characteristics on the other hand generally allow the metal to be deformed and restrained in the deformed condition to facilitate the insertion of the medical device containing the metal into a patient's body, with such deformation causing the phase transformation. Once within the body lumen the restraint on the superelastic member can be removed, thereby reducing the stress therein so that the superelastic member can return to t5 its original un-deformed shape by the transformation back to the original phase.
Alloys having shape memory/superelastic characteristics generally have at least two phases. These phases are a martensite phase, which has a relatively low tensile strength and which is stable at relatively low temperatures, and an austenite phase, which has a relatively high tensile strength and which is stable at temperatures higher than the martensite phase.
2o Shape memory characteristics are imparted to the alloy by heating the metal at a temperature above which the transformation from the martensite phase to the austenite phase is complete, i.e. a temperature above which the austenite phase is stable (the Af tanperat<ue). The shape of the metal during this heat treatment is the shape "remembered". The heat treated metal is cooled to a temperature at which the martensite phase is stable, causing the austenite phase to 25 transform to the martensite phase. The metal in the martensite phase is then pla~ically deformed, e.g. to facilitate the entry thereof into a patient's body. Subsequent heating of the deformed marta>site phase to a temperature above the martei~site to austenite transformation temperature causes the deformed martensite phase to transform to the austenite phase and during this phase transformation the metal reverts back to its original shape if unrestrained.
If restrained, the metal 3o will remain martensitic until the restraint is removed.
IMPROVED STRUT CONFIGURATION
Mark Mathis Thomas Duerig FIELD OF THE 1)WENTION
The present invention relates to an expandable intraluminal grafts ("stents") for use within a body passageway or duct which are particularly useful for repairing blood vessels narrowed or to occluded by disease. The present invention relates even further to such stents which are self expanding and made from a superelastic material such as Nitinol. The present invention also relates to delivery systems for such stents.
BACKGROUND OF THE INVENTION
15 Percutaneous transluminal coronary angioplasty (PTCA) is a therapeutic medical procedure used to increase blood flow through the coronary artery and can often be used as an alternative to coronary by-pass surgery. In this procedure, the angioplasty balloon is inflated within the stenosed vessel, or body passageway, in order to shear and disrupt the wall components of the vessel to obtain an enlarged lumen. With respect to arterial stenosed lesions, 2o the relatively incompressible plaque remains unaltered, while the more elastic medial and adventitial layers of the body passageway stretch around the plaque. This process produces dissection, or a splitting and tearing, of the body passageway wall layers, wherein the i~ima, or internal surface of the artery or body passageway, suffers fissuring. This dissection forms a "flap"
of underlying tissue which may reduce the blood flow through the lumen, or block the lumen.
25 Typically, the distending intraluminal pressure within the body passageway can hold the disrupted layer, or flap, in place. If the intimal flap created by the balloon dilation procedure is not maintained in place against the expanded intima, the intimal flap can fold down into the hunen and close off the lumen, or may even become detached and enter the body passageway. When the intimal flap closes off the body passageway, immediate surgery is necessary to correct this 3o problem.
/v 'D~ - 7 Recently, transluminal prostheses have been widely used in the medical arts for implantation in blood vessels, biliary ducts, or other similar organs of the living body. These prostheses are commonly known as scents and are used to maintain, open, or dilate tubular structures. An example of a commonly used stent is given in U.S. Patent 4,733,665 filed by Palmaz on November 7, 1985, which is hereby incorporated herein by reference.
Such stents are often referred to as balloon expandable stents. Typically the stent is made from a solid tube of stainless steel. Thereafter, a series of cuts are made in the wall of the stent. The stent has a first smaller diameter which permits the stmt to be delivered through the human vasculature by being crimped onto a balloon catheter. The stent also has a second, expanded diameter, upon the 1o application, by the balloon catheter, from the interior of the tubular shaped member of a radially, outwardly extending.
However, such stents are often impractical for use in some vessels such as the carotid artery. The carotid artery is easily accessible from the exterior of the human body, and is often visible by looking at ones neck. A patient having a balloon expandable stent made from stainless 1s steel or the like, placed in their carotid artery might be susceptible to sever injury through day to day activity. A sufficient force placed on the patients neck, such as by falling, could cause the stent to collapse, resulting in injury to the patient. In order to prevent this, self expanding stents have been proposed for use in such vessels. Self expanding stents act like springs and will recover to their expanded or implanted configuration after being crushed.
2o One type of self-expanding stent is disclosed in U.S. Patent 4,665,771, which stent has a radially and axially flexible, elastic tubular body with a predetermined diameter that is variable under axial movement of ends of the body relative to each other and which is composed of a plurality of individually rigid but flexible and elastic thread elements defining a radially self expanding helix. This type of stent is known in the art as a "braided stent"
and is so designated 2s herein. Placement of such stents in a body vessel can be achieved by a device which comprise an outer catheter for holding the stent at its distal end, and an inner piston which pushes the stent forward once it is in position.
However, braided stents have many disadvantages. They typically do not have the necessary radial strength to effectively hold open a diseased vessel. In addition, the plurality of 3o wires or fibers used to make such stents could become dangerous if separated from the body of the stent, where it could pierce through the vessel. Therefore, there has been a desire to have a self expanding stent, which is cut from a tube of metal, which is the common manufacturing method for many commercially available balloon expandable stents. In order to manufacture a self-expanding stent cut from a tube, the alloy used would preferably be superelastic or psuedoelastic characteristics at body temperature, so that it is crush recoverable.
The prior art makes reference to the use of alloys such as Nitinol (Ni-Ti alloy) which have shape memory and/or superdastic characteristics in medical devices which are designed to be inserted into a patient's body. The shape memory characteristics allow the devices to be deformed to facilitate their insertion iMo a body lumen or cavity and then be heated within the body so that 1o the device returns to its original shape. Superelastic characteristics on the other hand generally allow the metal to be deformed and restrained in the deformed condition to facilitate the insertion of the medical device containing the metal into a patient's body, with such deformation causing the phase transformation. Once within the body lumen the restraint on the superelastic member can be removed, thereby reducing the stress therein so that the superelastic member can return to t5 its original un-deformed shape by the transformation back to the original phase.
Alloys having shape memory/superelastic characteristics generally have at least two phases. These phases are a martensite phase, which has a relatively low tensile strength and which is stable at relatively low temperatures, and an austenite phase, which has a relatively high tensile strength and which is stable at temperatures higher than the martensite phase.
2o Shape memory characteristics are imparted to the alloy by heating the metal at a temperature above which the transformation from the martensite phase to the austenite phase is complete, i.e. a temperature above which the austenite phase is stable (the Af tanperat<ue). The shape of the metal during this heat treatment is the shape "remembered". The heat treated metal is cooled to a temperature at which the martensite phase is stable, causing the austenite phase to 25 transform to the martensite phase. The metal in the martensite phase is then pla~ically deformed, e.g. to facilitate the entry thereof into a patient's body. Subsequent heating of the deformed marta>site phase to a temperature above the martei~site to austenite transformation temperature causes the deformed martensite phase to transform to the austenite phase and during this phase transformation the metal reverts back to its original shape if unrestrained.
If restrained, the metal 3o will remain martensitic until the restraint is removed.
A
Methods of using the shape memory characteristics of these alloys in medical devices intended to be placed within a patient's body present operational difficulties. For example, with shape memory alloys having a stable martensite temperature below body temperature, it is frequently difficult to maintain the temperature of the medical device containing such an alloy sufficiently below body temperature to prevent the transformation of the martensite phase to the austenite phase when the device was being inserted into a patient's body. With intravascular devices formed of shape memory alloys having martensite-to-austenite transformation temperatures well above body temperature, the devices can be introduced into a patient's body with little or no problem, but they must be heated to the martensite-to-austenite transformation to temperature which is frequently high enough to cause tissue damage and very high levels of pain.
When stress is applied to a specimen of a metal such as Nltinol exhibiting superelastic characteristics at a temperature above which the austenite is stable (i.e. the temperature at which the transformation of martensite phase to the austenite phase is complete), the specimen deforms elastically until it reaches a particular stress level where the alloy then undergoes a stress-induced 1s phase transformation from the austenite phase to the martensite phase. As the phase transformation proceeds, the alloy undergoes significant increases in strain but with little or no corresponding increases in stress. The strain increases while the stress remains essentially constant until the transformation of the austenite phase to the martensite phase is complete.
Thereafter, fiuther increase in stress are necessary to cause fiuther deformation. The martensitic 2o metal first deforms elastically upon the application of additional stress and then plastically with permanent residual deformation.
If the load on the specimen is removed before any permanent deformation has occurred, the martensitic specimen will elastically recover and transform back to the sustenite phase. The reduction in stress first causes a decrease in strain. As stress reduction reaches the level at which 2s the martensite phase transforms back into the austenite phase, the stress level in the will remain essentially constant (but substantially less than the constant stress level at which the austenite transforms to the martensite) until the transformation back to the sustenite phase is complete, i.e. there is significant recovery in strain with only negligible corresponding stress reduction. After the transformation back to austenite is complete, further stress reduction results 3o in elastic strain reduction. This ability to incur significant strain at relatively constant stress upon the application of a load and to recover from the deformation upon the removal of the load is commonly referred to as superelasticity or pseudoelasticity. It is this property of the material which makes it useful in manufacturing tube cut self-expanding starts. The prior art makes reference to the use of metal alloys having superelastic characteristics in medical devices which are intended to be inserted or otherwise used within a patient's body. See for example, U. S. Pat.
No. 4,665,905 (Jervis) and U.S. Pat. No. 4,925,445 (Sakamoto et al.).
However, the prior art has yet to disclose any suitable tube cut self expanding starts. In addition, many of the prior art sterrts lacked the necessary rigidity or hoop strength to keep the body vessel open. In addition, many of the prior art starts have large openings at their expanded to diameter. The smaller the openings are on an expanded start, the more plaque or other deposits it can trap between the start and the vessel wall. Trapping these deposits is important to the continuing health of the patient in that it helps prevent stokes as well as helps prevents restenosis of the vessel it is implanted into. The present invention provides for a self expanding tube cut start which overcomes many of the disadvantages associated with the prior art starts.
SUMMARY OF THE INVENTION
In accordance with the present invention, there is provided a start for insertion into a vessel of a patient the slant is a tubular member with a predetermined a thickness. The member has front and back open ends and a longitudinal axis extending therebetween.
The slant has a first 2o smaller diameter for insertion into the vessel, and a second larger diameter for deployment into the vessel. The tubular member includes a plurality of adjacent hoops extending between the front and back ends. The hoops are made from a plurality of longitudinal struts and a plurality of loops connecting adjacent struts. The member further includes a plurality of bridges connecting adjacent hoops to one another. The individual struts have lengths, as measured parallel to the longitudinal axis. The ster~t is constructed so that the ratio of the number of struts per hoop to the length of a strut, as measured in inches, is greater than about 400.
BRIEF DESCRIPTION OF DRAWINGS
Methods of using the shape memory characteristics of these alloys in medical devices intended to be placed within a patient's body present operational difficulties. For example, with shape memory alloys having a stable martensite temperature below body temperature, it is frequently difficult to maintain the temperature of the medical device containing such an alloy sufficiently below body temperature to prevent the transformation of the martensite phase to the austenite phase when the device was being inserted into a patient's body. With intravascular devices formed of shape memory alloys having martensite-to-austenite transformation temperatures well above body temperature, the devices can be introduced into a patient's body with little or no problem, but they must be heated to the martensite-to-austenite transformation to temperature which is frequently high enough to cause tissue damage and very high levels of pain.
When stress is applied to a specimen of a metal such as Nltinol exhibiting superelastic characteristics at a temperature above which the austenite is stable (i.e. the temperature at which the transformation of martensite phase to the austenite phase is complete), the specimen deforms elastically until it reaches a particular stress level where the alloy then undergoes a stress-induced 1s phase transformation from the austenite phase to the martensite phase. As the phase transformation proceeds, the alloy undergoes significant increases in strain but with little or no corresponding increases in stress. The strain increases while the stress remains essentially constant until the transformation of the austenite phase to the martensite phase is complete.
Thereafter, fiuther increase in stress are necessary to cause fiuther deformation. The martensitic 2o metal first deforms elastically upon the application of additional stress and then plastically with permanent residual deformation.
If the load on the specimen is removed before any permanent deformation has occurred, the martensitic specimen will elastically recover and transform back to the sustenite phase. The reduction in stress first causes a decrease in strain. As stress reduction reaches the level at which 2s the martensite phase transforms back into the austenite phase, the stress level in the will remain essentially constant (but substantially less than the constant stress level at which the austenite transforms to the martensite) until the transformation back to the sustenite phase is complete, i.e. there is significant recovery in strain with only negligible corresponding stress reduction. After the transformation back to austenite is complete, further stress reduction results 3o in elastic strain reduction. This ability to incur significant strain at relatively constant stress upon the application of a load and to recover from the deformation upon the removal of the load is commonly referred to as superelasticity or pseudoelasticity. It is this property of the material which makes it useful in manufacturing tube cut self-expanding starts. The prior art makes reference to the use of metal alloys having superelastic characteristics in medical devices which are intended to be inserted or otherwise used within a patient's body. See for example, U. S. Pat.
No. 4,665,905 (Jervis) and U.S. Pat. No. 4,925,445 (Sakamoto et al.).
However, the prior art has yet to disclose any suitable tube cut self expanding starts. In addition, many of the prior art sterrts lacked the necessary rigidity or hoop strength to keep the body vessel open. In addition, many of the prior art starts have large openings at their expanded to diameter. The smaller the openings are on an expanded start, the more plaque or other deposits it can trap between the start and the vessel wall. Trapping these deposits is important to the continuing health of the patient in that it helps prevent stokes as well as helps prevents restenosis of the vessel it is implanted into. The present invention provides for a self expanding tube cut start which overcomes many of the disadvantages associated with the prior art starts.
SUMMARY OF THE INVENTION
In accordance with the present invention, there is provided a start for insertion into a vessel of a patient the slant is a tubular member with a predetermined a thickness. The member has front and back open ends and a longitudinal axis extending therebetween.
The slant has a first 2o smaller diameter for insertion into the vessel, and a second larger diameter for deployment into the vessel. The tubular member includes a plurality of adjacent hoops extending between the front and back ends. The hoops are made from a plurality of longitudinal struts and a plurality of loops connecting adjacent struts. The member further includes a plurality of bridges connecting adjacent hoops to one another. The individual struts have lengths, as measured parallel to the longitudinal axis. The ster~t is constructed so that the ratio of the number of struts per hoop to the length of a strut, as measured in inches, is greater than about 400.
BRIEF DESCRIPTION OF DRAWINGS
The foregoing and other aspects of the present invention will best be appreciated with reference to the detailed description of the invention in conjunction with the accompanying drawings, wherein:
Figure 1 is a simplified partial cross-sectional view of a stent delivery apparatus having a stent loaded therein, which can be used with a stent made in accordance with the present invention.
Figure 2 is a view similar to that of figure 1 but showing an enlarged view of the distal end of the apparatus.
Figure 3 is a perspective view of a stent made in accordance with the present invention, 1o showing the stent in its compressed state.
Figure 4 is a sectional, flat view of the stent shown in Figure 1.
Figure 4~ is an enlarged view of section of the stent shown in Figure 4.
Figure 5 is a perspective view of the stmt shown in Figure 1 but showing it in its expanded state.
Figure 6 is an enlarged sectional view of the stent shown in Figure 5.
Figure 7 is a view similar to that of Figure 4 but showing an alternative embodiment of the present invention.
2o DETAILED DESCRIPTION OF THE INVENTION
Referring now to the figures wherein like ~merals indicate the same element throughout the views, there is shown in Figures 3 and 4, a stent 50 made in accordance with the present invention. Figures 3 and 4 show stent 50 in its un-expanded or compressed state. Stent 50 is preferably made from a superelastic alloy such as Ntinol. Most preferably, stent 50 is made from 2s an alloy comprising from about 50.5% (as used herein these percentages refer to atomic percentages) N to about 60% Ni, and most preferably about 55% Ni, with the remainder of the alloy Ti. Preferably, the stent is such that it is superelastic at body temperature, and preferably has an Af in the range from about 24° C to about 37° C. The superelastic design of the stmt makes it crush recoverable which, as discussed above, can be used as a stent or frame for any 3o number of vascular devices for different applications.
Figure 1 is a simplified partial cross-sectional view of a stent delivery apparatus having a stent loaded therein, which can be used with a stent made in accordance with the present invention.
Figure 2 is a view similar to that of figure 1 but showing an enlarged view of the distal end of the apparatus.
Figure 3 is a perspective view of a stent made in accordance with the present invention, 1o showing the stent in its compressed state.
Figure 4 is a sectional, flat view of the stent shown in Figure 1.
Figure 4~ is an enlarged view of section of the stent shown in Figure 4.
Figure 5 is a perspective view of the stmt shown in Figure 1 but showing it in its expanded state.
Figure 6 is an enlarged sectional view of the stent shown in Figure 5.
Figure 7 is a view similar to that of Figure 4 but showing an alternative embodiment of the present invention.
2o DETAILED DESCRIPTION OF THE INVENTION
Referring now to the figures wherein like ~merals indicate the same element throughout the views, there is shown in Figures 3 and 4, a stent 50 made in accordance with the present invention. Figures 3 and 4 show stent 50 in its un-expanded or compressed state. Stent 50 is preferably made from a superelastic alloy such as Ntinol. Most preferably, stent 50 is made from 2s an alloy comprising from about 50.5% (as used herein these percentages refer to atomic percentages) N to about 60% Ni, and most preferably about 55% Ni, with the remainder of the alloy Ti. Preferably, the stent is such that it is superelastic at body temperature, and preferably has an Af in the range from about 24° C to about 37° C. The superelastic design of the stmt makes it crush recoverable which, as discussed above, can be used as a stent or frame for any 3o number of vascular devices for different applications.
Stent 50 is a tubular member having front and back open ends 81 and 82 and a longitudinal axis 83 extending therebetween. The tubular member has a first smaller diameter, figures 3 and 4, for insertion into a patient and navigation through the vessels, and a second larger diameter, figures 5 and 6, for deployment into the target area of a vessel.
The tubular member is made from a plurality of adjacent hoops 52, figure 1 showing hoops 52(a) -52(b), extending between the front and back ends 81 and 82. The hoops 52 include a plurality of longitudinal struts 60 and a plurality of loops 62 connecting adjacent struts, wherein adjacent struts are connected at opposite ends so as to form an S or Z shape pattern. The loops 62 are curved substantially semi-circular and symmetrical sections having centers 64.
1o Stent 50 further includes a plurality of bridges 70 which connect adjacent hoops 52 which can best be described by referring to Figure 4. Each bridge has two ends 56 and 58. The bridges have one end attached to one strut and/or loop, another end attached to a stmt and/or loop on an adjacent hoop. Bridges 70 conned adjacent struts together at bridge to loop connection points 72 and 74. For example, end 56 is connected to loop 64(a) at bridge to loop connection point 72, ~5 and end 58 is connected to loop 64(b) at bridge to loop connection point 74. Each bridge to loop connection points have centers 76. The bridge to loop connection points are separated angularly with respect to the longitudinal axis. That is the connection points are not immediately opposite each other. One could not draw a straight line between the connection points, wherein such line would be parallel to the longitudinal axis of the stent 2o The above described geometry helps to beuer distribute strain throughout the stent, prevents metal to metal contact when the stent is bent, and minimizes the opening size between the features, struts loops and bridges. The number of and nature of the design of the struts, loops and bridges are important factors when determining the working properties and fatigue life properties of the scent. It was previously thought that in order to improve the rigidity of the 25 scent, that struts should be large, and therefore then should be fewer stnrts per hoop. Hawevier, it has now been discovered that scents having smaller struts and more struts per hoop actually improve the construction of the scent and provide greater rigidity.
Preferably, each hoop hrrs between 24 to 36 or more struts. It has been determined that a scent having a ratio of number of struts per hoop to strut length L (in inches) which is greater than 400 has increased rigidity over prior art scents which typically had a ratio of under 200. The length of a strut is measured in its compressed state parallel to the longitudinal axis 83 0, f the scent.
As seen from Figures 3 and 4, the geometry of the stent changes quite significantly as a stent is deployed from its un-expanded state to its expanded state. As a stent undergoes diametric s change, the strut angle and strain levels in the loops and bridges are effected. Preferably, all of the stent features wiU strain in a predictable manor so that the stem is reliable and uniform in strength. In addition, it is preferable to minimize the maximum strain experienced by sluts loops and bridges, since Nitinol properties are more generally limited by strain rather than by stress as most materials are. As will be discussed in greater detail below, the scent sits in the delivery to system in its un-expanded state as shown in Figure 3. As the stmt is deployed, it is allowed to expand towards it's expanded state, as shown in Figure 4, which preferably has a diameter which is the same or larger than the diameter of the target vessel. Ntinol stents made from wire deploy in much the same manor and are dependent upon the same design constraints as laser cut stents.
Stainless steel stents deploy similarly in terms of geometric changes as they are assisted with 15 forces from balloons or other devices.
In trying to minimize the maximum strain experienced by features, the present invention utilizes structural geometry's which distribute strain to areas of the stent which are less susceptible to failure than others. For example, one of the most vulnerable areas of the stent is the inside radius of the connecting loops. The connecting loops undergo the most deformation 20 of all the stent features. The inside radius of the loop would normally be the area with the highest level of strain on the stent. This area is also critical in that it is u~ally the smallest radius on the stent. Stress concentrations are generally controlled or minimized by maintaining the largest radii possible. Similarly, we want to minimize local strain concentrations on the bridge and bridge connection points. One way to accomplish this is to utilize the largest possible radii while 25 maintaining feature widths which are consistent with applied forces.
Another consideration is to minimize the maximum open area of the stent. Efficient utilization of the original tube from which the stmt is cut increases stent strength and it's ability to trap embolic material.
Mater of these objectives have been accomplished by a preferred embodiment of the present invention, shown in Figures 3 and 4. As seen from these figures, the most compact 3o designs which maintain the largest radii at the loop to bridge connections are non-symmetric with s respect to the centerline of the strut connecting loop. That is, loop to bridge connection point centers 76 are off set from the center 64 of the loops 62 to which they are attached. The feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required.
Ntinol can s withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. This feature allows for maximum utilization of Ni-Ti or other material capabilities to enhance radial strength, improve stent strength uniformity, improves fatigue life by minimizing local strain levels, allows for smaller open areas which enhance entrapment of embolic material, and improves stent apposition in irregular vessel waU shapes and 1o curves.
As seen in figure 4A, stent 50 has strut connecting loops 62 having a width W4, as measured at the center 64 parallel to axis 83, which are greater than the strut widths W2, as measured perpendicular to axis 83 itself. In fact it is preferable that the thickness of the loops vary so that they are thickest near their centers This increases strain deformation at the strut and 15 reduces the maximum strain levels at the extreme radii of the loop. This reduces the risk of stmt failure and allows us to maximize radial strength properties. The feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required. Ntinol can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to 2o starts made from this alloy. This feature allows for maximum utilization of N-Ti or other material capabilities to enhance radial strength, improve start strength uniformity, improves fatigue life by minimizing local strain levels, allows for smaller open areas which enhance entrapment of embolic material, and improves start apposition in irregular vessel wall si~pes and curves.
25 As mentioned above bridge geometry changes as a start is deployed from its compressed state to its expanded state and vise-versa. As a start undergoes diametric change, strut angle and loop strain is effected. Since the bridges are connected to either the loops, struts or both, they are effected. twisting of one end of the stmt with respect to the other, while loaded in the stmt delivery system, should be avoided. Local torque delivered to the bridge ends displaces the bridge 3o geometry. If the bridge design is duplicated around the start perimeter, this displacement causes rotational shifting of the two loops being connected by the bridges. If the bridge design is duplicated throughout the scent, as in the present invention, this shift will occur down the length of the stent. This is a cumulative effect as one considers rotation of one end with respect to the other upon deployment. A stent delivery system, such as the one described below, will deploy the distal end first, then allow the proximal end to expand. It would be undesirable to allow the distal end to anchor into the vessel wall while holding the stem fixed in rotation, then release the proximal end. this could cause the stent to twist or whip in rotation to equilibrium after it is at least partially deployed within the vessel. Such whipping action could cause damage to the vessel.
However, one embodiment of the present invention, as shown in Figures 3 and 4, reduces 1o the chance of such events from happening when deploying the stent. By mirroring the bridge geometry longitudinally down the stent, the rotational shift of the Z-sections can be made to alternate and will minimize large rotational changes between any two points on a given stmt during deployment or constraint. That is the bridges connecting loop 52(b) to loop 52(c) are angled upwardly from left to right, while the bridges connecting loop 52(c) to loop 52(d) are angled downwardly from left to right. This alternating pattern is repeated down the length of the stent. This alternating pattern of bridge slopes improves the torsional characteristics of the stent so as to minimize any twisting or rotation of the stent with respect to any two hoops. This alternating bridge slope is particularly beneficial if the stent starts to twist in vivo. As the stent twists, the diameter of the stent will change. Alternating bridge slopes tend to minimize this 2o effect. The diameter of a stent having bridges which are all sloped in the same direction will tend grow if twisted in one direction and shrink if twisted in the other direction.
With alternating bridge slopes this effect is minimized and localized.
The feature is particularly advantageous for slants having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strums are required.
Nitinol can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to slants made from this alloy. This feature allows for maximum utilization of N
Ti or other material capabilities to enhance radial strength, improve slant uniformity, improves fatigue life by minimizing local strain levels, allows for smaller open areas which enhance entrapment of embolic material, and improves slant apposition in irregular vessel wall 3o shapes and curves.
to Preferably, stents are laser cut from small diameter tubing. For prior art stents, this manufacturing process lead to designs with geometric features, such as struts, loops and bridges, having axial widths W2, W4 and W3 (rvely) which are larger than the tube wall thickness T
(shown in Figure 5). When the stent is compressed, most of the bending occurs in the plane that is created if one were to cut longitudinally down the stent and flatten it out. However, for the individual bridges, loops and struts, which have widths greater than their thickness, they have a greater resistance to this in-plane bending than they do to out of plane bending. Because of this, the bridges and struts tend to twist, so that the stent as a whole can bend more easily. This twisting is a buckling condition which is unpredictable and can cause potentially high strain.
to However, this problem has been solved in a preferred embodiment of the present invention, shown in Figures 3 and 4. As seen from these figures, the widths of the struts, hoops and bridges are equal to or less than the wall thickness of the tube.
Therefore, substantially all bending and, therefore, all strains are "out of plane". This minimizes twisting of the stmt which minimizes or eliminates buckling and unpredictable strain conditions. The feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required. Ntinol can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. This feature allows for maximum utilization of Ni-Ti or other material capabilities to enhance radial strength, improve stent strength uniformity, improves fatigue life by minimizing local strain levels, allows for smaller open areas which enhance entrapment of embolic material, and improves stent apposition in irregular vessel wall shapes and curves.
An alternative embodiment of the present invention is shown in Figure 7.
Figure 7 shows stets 150 which is similar to stent 50 shown in the previous drawings. Stent 150 is made from a plurality of adjacent hoops 152, figure 7 showing hoops 152(a) - 152(d). The hoops 152 include a plurality of longitudinal struts 160 and a plurality of loops 162 connecting adjacent struts, wherein adjacent struts are connected at opposite ends so as to form an S or Z
shape pattern.
Stent 150 further includes a plurality of bridges 170 which connect adjacent hoops 152. As seen from the figure, bridges 170 are non-linear and curve between adjacent hoops.
Having curved 3o bridges allows the bridges to curve around the loops and struts so that the hoops to be placed proximal and distal ends 12 and 14 respectively. the distal end 14 of the shaft terminates at a luer lock hub 5. Preferably, shaft 10 has a proximal portion 16 which is made from a relatively stiff material such as stainless steel, Ntinol, or any other suitable material, and an distal portion 18 which is made from a polyethylene, polyimide, pellethane, Pebax, Vestamid, Cristamid, Grillamid or any other suitable material known to those of ordinary skill in the art..
The two portions are joined together by any number of means known to those of ordinary skill in the art. The stainless steel proximal end gives the shaft the necessary rigidity or stiffness it needs to effectively push out the stent, while the polymeric distal portion provides the necessary flexibility to navigate tortuous vessels.
to The distal portion 18 of the shaft has a distal tip 20 attached thereto.
The distal tip 20 has a proximal end 34 whose diameter is substantially the same as the outer diameter of the sheath 40.
The distal tip tapers to a smaller diameter from its proximal end to its distal end, wherein the distal end 36 of the distal tip has a diameter smaller than the inner diameter of the sheath. Also attached to distal portion 18 of shaft 10 is a stop 22 which is proximal to the distal tip 20. Stop 22 can be made from any number of materials known in the art, including stainless steel, and is even more preferably made from a highly radiopaque material such as platinum, gold tantalum. The diameter of stop 22 is substantially the same as the inner diameter of sheath 40, and would acxually make frictional contact with the inner surface of the sheath. Stop 22 helps to push the stent out of the sheath during deployment, and helps the stent from migrating proximally into the sheath 40.
2o A stent bed 24 is defined as being that portion of the shaft between the distal tip 20 and the stop 22. The stent bed 24 and the stent 50 are coaxial so that the portion of shaft 18 comprising the slant bed 24 is located within the lumen of the stent 50.
However, the stmt bed 24 does not make amr contact with stmt 50 itself. Lastly, shaft 10 has a guidewire lumen 28 extending along its length from its proximal end 12 and exiting through its distal tip 20. This allows the shaft 10 to receive a guidewire much in the same way that an ordinary balloon angioplastly catheter receives a guidewire. Such guidewires are well known in art sad help guide catheters and other medical devices through the vasculature of the body.
Sheath 40 is preferably a polymeric catheter and has a proximal end 42 terminating at a hub 52. Sheath 40 also has a distal end 44 which terminates at the proximal end 34 of distal tip 20 of the shaft 18, when the stets is in its fully un-deployed position as shown in the 5gures. The distal end 44 of sheath 40 includes a radiopaque marker band 46 disposed along its outer surface.
As will be explained below, the stent is fully deployed when the marker band 46 is lined up with radiopaque stop 22, thus indicating to the physician that it, is now safe to remove the apparatus 1 from the body. Sheath 40 preferably comprises an outer polymeric layer and an inner polymeric layer. Positioned between outer and inner layers a braided reinforcing layer.
Braided reinforcing layer is preferably made from stainless steel. The use of braided reinforcing layers in other types of medical devices can be found in U.S. patents 3,585,707 issued to Stevens on June 22, 1971, 5,045,072 issued to Castillo et al. on September 3, 1991, and 5,254,107 issued to Soltesz on October 19, 1993, all of which are hereby incorporated herein by reference.
to Figures 1 and 2 show the stent 50 as being in its fully un-deployed position. This is the position the slant is in when the apparatus 1 is inserted into the vasculature and its distal end is navigated to a target site. Stent 50 is disposed around slant bed 24 and at the distal end 44 of sheath 40. The distal tip 20 of the shaft 10 is distal to the distal end 44 of the sheath 40, and the proximal end 12 of the shaft 10 is proximal to the proximal end 42 of the sheath 40. The stem 50 is in a compressed state and makes frictional contact with the inner surface 48 of the sheath 40.
When being inserted into a patient, sheath 40 and shaft 10 are locked together at their proximal ends by a Touhy Borst valve 8. This prevents any sliding movement between the shaft and sheath which could result in a premature deployment or partial deployment of the slant.
When the slant 50 reaches its target site and is ready for deployment, the Tou6y Borst valve 8 is opened so that that the sheath 40 and shaft 10 are no longer locked together.
The method under which apparatus 1 deploys slant 50 should be readily apparent. The apparatus 1 is first inserted into a vessel so that the slant bed 24 is at a target diseased site. Once this has occurred the physician would open the Touhy Borst valve 8. The physician would then grasp the proximal end 12 of shaft 10 so as to hold it in place. Thereafter, the physician would grasp the pmxirnal end 42 of sheath 40 and slide it proximal, relative to the shaft 40. Stop 22 prevents the slant 50 from sliding back with the sheath 40, so that as the sheath 40 is moved back, the slant SO is pushed out of the distal end 44 of fhe sheath 40. Stent deployment is complete when the radiopaque band 46 on the sheath 40 is proximal to radiopaque stop 22. The apparatus 1 can now be withdrawn through slant 50 and removed from the patient.
Although particular embodiments of the present invention have been shown and described, modification may be made to the device and/or method without departing from the spirit and scope of the present invention. The terms used in describing the invention are used in their descriptive sense and not as terms of limitations.
THAT WHICH IS CLAI1VVIED IS:
The tubular member is made from a plurality of adjacent hoops 52, figure 1 showing hoops 52(a) -52(b), extending between the front and back ends 81 and 82. The hoops 52 include a plurality of longitudinal struts 60 and a plurality of loops 62 connecting adjacent struts, wherein adjacent struts are connected at opposite ends so as to form an S or Z shape pattern. The loops 62 are curved substantially semi-circular and symmetrical sections having centers 64.
1o Stent 50 further includes a plurality of bridges 70 which connect adjacent hoops 52 which can best be described by referring to Figure 4. Each bridge has two ends 56 and 58. The bridges have one end attached to one strut and/or loop, another end attached to a stmt and/or loop on an adjacent hoop. Bridges 70 conned adjacent struts together at bridge to loop connection points 72 and 74. For example, end 56 is connected to loop 64(a) at bridge to loop connection point 72, ~5 and end 58 is connected to loop 64(b) at bridge to loop connection point 74. Each bridge to loop connection points have centers 76. The bridge to loop connection points are separated angularly with respect to the longitudinal axis. That is the connection points are not immediately opposite each other. One could not draw a straight line between the connection points, wherein such line would be parallel to the longitudinal axis of the stent 2o The above described geometry helps to beuer distribute strain throughout the stent, prevents metal to metal contact when the stent is bent, and minimizes the opening size between the features, struts loops and bridges. The number of and nature of the design of the struts, loops and bridges are important factors when determining the working properties and fatigue life properties of the scent. It was previously thought that in order to improve the rigidity of the 25 scent, that struts should be large, and therefore then should be fewer stnrts per hoop. Hawevier, it has now been discovered that scents having smaller struts and more struts per hoop actually improve the construction of the scent and provide greater rigidity.
Preferably, each hoop hrrs between 24 to 36 or more struts. It has been determined that a scent having a ratio of number of struts per hoop to strut length L (in inches) which is greater than 400 has increased rigidity over prior art scents which typically had a ratio of under 200. The length of a strut is measured in its compressed state parallel to the longitudinal axis 83 0, f the scent.
As seen from Figures 3 and 4, the geometry of the stent changes quite significantly as a stent is deployed from its un-expanded state to its expanded state. As a stent undergoes diametric s change, the strut angle and strain levels in the loops and bridges are effected. Preferably, all of the stent features wiU strain in a predictable manor so that the stem is reliable and uniform in strength. In addition, it is preferable to minimize the maximum strain experienced by sluts loops and bridges, since Nitinol properties are more generally limited by strain rather than by stress as most materials are. As will be discussed in greater detail below, the scent sits in the delivery to system in its un-expanded state as shown in Figure 3. As the stmt is deployed, it is allowed to expand towards it's expanded state, as shown in Figure 4, which preferably has a diameter which is the same or larger than the diameter of the target vessel. Ntinol stents made from wire deploy in much the same manor and are dependent upon the same design constraints as laser cut stents.
Stainless steel stents deploy similarly in terms of geometric changes as they are assisted with 15 forces from balloons or other devices.
In trying to minimize the maximum strain experienced by features, the present invention utilizes structural geometry's which distribute strain to areas of the stent which are less susceptible to failure than others. For example, one of the most vulnerable areas of the stent is the inside radius of the connecting loops. The connecting loops undergo the most deformation 20 of all the stent features. The inside radius of the loop would normally be the area with the highest level of strain on the stent. This area is also critical in that it is u~ally the smallest radius on the stent. Stress concentrations are generally controlled or minimized by maintaining the largest radii possible. Similarly, we want to minimize local strain concentrations on the bridge and bridge connection points. One way to accomplish this is to utilize the largest possible radii while 25 maintaining feature widths which are consistent with applied forces.
Another consideration is to minimize the maximum open area of the stent. Efficient utilization of the original tube from which the stmt is cut increases stent strength and it's ability to trap embolic material.
Mater of these objectives have been accomplished by a preferred embodiment of the present invention, shown in Figures 3 and 4. As seen from these figures, the most compact 3o designs which maintain the largest radii at the loop to bridge connections are non-symmetric with s respect to the centerline of the strut connecting loop. That is, loop to bridge connection point centers 76 are off set from the center 64 of the loops 62 to which they are attached. The feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required.
Ntinol can s withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. This feature allows for maximum utilization of Ni-Ti or other material capabilities to enhance radial strength, improve stent strength uniformity, improves fatigue life by minimizing local strain levels, allows for smaller open areas which enhance entrapment of embolic material, and improves stent apposition in irregular vessel waU shapes and 1o curves.
As seen in figure 4A, stent 50 has strut connecting loops 62 having a width W4, as measured at the center 64 parallel to axis 83, which are greater than the strut widths W2, as measured perpendicular to axis 83 itself. In fact it is preferable that the thickness of the loops vary so that they are thickest near their centers This increases strain deformation at the strut and 15 reduces the maximum strain levels at the extreme radii of the loop. This reduces the risk of stmt failure and allows us to maximize radial strength properties. The feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required. Ntinol can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to 2o starts made from this alloy. This feature allows for maximum utilization of N-Ti or other material capabilities to enhance radial strength, improve start strength uniformity, improves fatigue life by minimizing local strain levels, allows for smaller open areas which enhance entrapment of embolic material, and improves start apposition in irregular vessel wall si~pes and curves.
25 As mentioned above bridge geometry changes as a start is deployed from its compressed state to its expanded state and vise-versa. As a start undergoes diametric change, strut angle and loop strain is effected. Since the bridges are connected to either the loops, struts or both, they are effected. twisting of one end of the stmt with respect to the other, while loaded in the stmt delivery system, should be avoided. Local torque delivered to the bridge ends displaces the bridge 3o geometry. If the bridge design is duplicated around the start perimeter, this displacement causes rotational shifting of the two loops being connected by the bridges. If the bridge design is duplicated throughout the scent, as in the present invention, this shift will occur down the length of the stent. This is a cumulative effect as one considers rotation of one end with respect to the other upon deployment. A stent delivery system, such as the one described below, will deploy the distal end first, then allow the proximal end to expand. It would be undesirable to allow the distal end to anchor into the vessel wall while holding the stem fixed in rotation, then release the proximal end. this could cause the stent to twist or whip in rotation to equilibrium after it is at least partially deployed within the vessel. Such whipping action could cause damage to the vessel.
However, one embodiment of the present invention, as shown in Figures 3 and 4, reduces 1o the chance of such events from happening when deploying the stent. By mirroring the bridge geometry longitudinally down the stent, the rotational shift of the Z-sections can be made to alternate and will minimize large rotational changes between any two points on a given stmt during deployment or constraint. That is the bridges connecting loop 52(b) to loop 52(c) are angled upwardly from left to right, while the bridges connecting loop 52(c) to loop 52(d) are angled downwardly from left to right. This alternating pattern is repeated down the length of the stent. This alternating pattern of bridge slopes improves the torsional characteristics of the stent so as to minimize any twisting or rotation of the stent with respect to any two hoops. This alternating bridge slope is particularly beneficial if the stent starts to twist in vivo. As the stent twists, the diameter of the stent will change. Alternating bridge slopes tend to minimize this 2o effect. The diameter of a stent having bridges which are all sloped in the same direction will tend grow if twisted in one direction and shrink if twisted in the other direction.
With alternating bridge slopes this effect is minimized and localized.
The feature is particularly advantageous for slants having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strums are required.
Nitinol can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to slants made from this alloy. This feature allows for maximum utilization of N
Ti or other material capabilities to enhance radial strength, improve slant uniformity, improves fatigue life by minimizing local strain levels, allows for smaller open areas which enhance entrapment of embolic material, and improves slant apposition in irregular vessel wall 3o shapes and curves.
to Preferably, stents are laser cut from small diameter tubing. For prior art stents, this manufacturing process lead to designs with geometric features, such as struts, loops and bridges, having axial widths W2, W4 and W3 (rvely) which are larger than the tube wall thickness T
(shown in Figure 5). When the stent is compressed, most of the bending occurs in the plane that is created if one were to cut longitudinally down the stent and flatten it out. However, for the individual bridges, loops and struts, which have widths greater than their thickness, they have a greater resistance to this in-plane bending than they do to out of plane bending. Because of this, the bridges and struts tend to twist, so that the stent as a whole can bend more easily. This twisting is a buckling condition which is unpredictable and can cause potentially high strain.
to However, this problem has been solved in a preferred embodiment of the present invention, shown in Figures 3 and 4. As seen from these figures, the widths of the struts, hoops and bridges are equal to or less than the wall thickness of the tube.
Therefore, substantially all bending and, therefore, all strains are "out of plane". This minimizes twisting of the stmt which minimizes or eliminates buckling and unpredictable strain conditions. The feature is particularly advantageous for stents having large expansion ratios, which in turn requires them to have extreme bending requirements where large elastic strains are required. Ntinol can withstand extremely large amounts of elastic strain deformation, so the above features are well suited to stents made from this alloy. This feature allows for maximum utilization of Ni-Ti or other material capabilities to enhance radial strength, improve stent strength uniformity, improves fatigue life by minimizing local strain levels, allows for smaller open areas which enhance entrapment of embolic material, and improves stent apposition in irregular vessel wall shapes and curves.
An alternative embodiment of the present invention is shown in Figure 7.
Figure 7 shows stets 150 which is similar to stent 50 shown in the previous drawings. Stent 150 is made from a plurality of adjacent hoops 152, figure 7 showing hoops 152(a) - 152(d). The hoops 152 include a plurality of longitudinal struts 160 and a plurality of loops 162 connecting adjacent struts, wherein adjacent struts are connected at opposite ends so as to form an S or Z
shape pattern.
Stent 150 further includes a plurality of bridges 170 which connect adjacent hoops 152. As seen from the figure, bridges 170 are non-linear and curve between adjacent hoops.
Having curved 3o bridges allows the bridges to curve around the loops and struts so that the hoops to be placed proximal and distal ends 12 and 14 respectively. the distal end 14 of the shaft terminates at a luer lock hub 5. Preferably, shaft 10 has a proximal portion 16 which is made from a relatively stiff material such as stainless steel, Ntinol, or any other suitable material, and an distal portion 18 which is made from a polyethylene, polyimide, pellethane, Pebax, Vestamid, Cristamid, Grillamid or any other suitable material known to those of ordinary skill in the art..
The two portions are joined together by any number of means known to those of ordinary skill in the art. The stainless steel proximal end gives the shaft the necessary rigidity or stiffness it needs to effectively push out the stent, while the polymeric distal portion provides the necessary flexibility to navigate tortuous vessels.
to The distal portion 18 of the shaft has a distal tip 20 attached thereto.
The distal tip 20 has a proximal end 34 whose diameter is substantially the same as the outer diameter of the sheath 40.
The distal tip tapers to a smaller diameter from its proximal end to its distal end, wherein the distal end 36 of the distal tip has a diameter smaller than the inner diameter of the sheath. Also attached to distal portion 18 of shaft 10 is a stop 22 which is proximal to the distal tip 20. Stop 22 can be made from any number of materials known in the art, including stainless steel, and is even more preferably made from a highly radiopaque material such as platinum, gold tantalum. The diameter of stop 22 is substantially the same as the inner diameter of sheath 40, and would acxually make frictional contact with the inner surface of the sheath. Stop 22 helps to push the stent out of the sheath during deployment, and helps the stent from migrating proximally into the sheath 40.
2o A stent bed 24 is defined as being that portion of the shaft between the distal tip 20 and the stop 22. The stent bed 24 and the stent 50 are coaxial so that the portion of shaft 18 comprising the slant bed 24 is located within the lumen of the stent 50.
However, the stmt bed 24 does not make amr contact with stmt 50 itself. Lastly, shaft 10 has a guidewire lumen 28 extending along its length from its proximal end 12 and exiting through its distal tip 20. This allows the shaft 10 to receive a guidewire much in the same way that an ordinary balloon angioplastly catheter receives a guidewire. Such guidewires are well known in art sad help guide catheters and other medical devices through the vasculature of the body.
Sheath 40 is preferably a polymeric catheter and has a proximal end 42 terminating at a hub 52. Sheath 40 also has a distal end 44 which terminates at the proximal end 34 of distal tip 20 of the shaft 18, when the stets is in its fully un-deployed position as shown in the 5gures. The distal end 44 of sheath 40 includes a radiopaque marker band 46 disposed along its outer surface.
As will be explained below, the stent is fully deployed when the marker band 46 is lined up with radiopaque stop 22, thus indicating to the physician that it, is now safe to remove the apparatus 1 from the body. Sheath 40 preferably comprises an outer polymeric layer and an inner polymeric layer. Positioned between outer and inner layers a braided reinforcing layer.
Braided reinforcing layer is preferably made from stainless steel. The use of braided reinforcing layers in other types of medical devices can be found in U.S. patents 3,585,707 issued to Stevens on June 22, 1971, 5,045,072 issued to Castillo et al. on September 3, 1991, and 5,254,107 issued to Soltesz on October 19, 1993, all of which are hereby incorporated herein by reference.
to Figures 1 and 2 show the stent 50 as being in its fully un-deployed position. This is the position the slant is in when the apparatus 1 is inserted into the vasculature and its distal end is navigated to a target site. Stent 50 is disposed around slant bed 24 and at the distal end 44 of sheath 40. The distal tip 20 of the shaft 10 is distal to the distal end 44 of the sheath 40, and the proximal end 12 of the shaft 10 is proximal to the proximal end 42 of the sheath 40. The stem 50 is in a compressed state and makes frictional contact with the inner surface 48 of the sheath 40.
When being inserted into a patient, sheath 40 and shaft 10 are locked together at their proximal ends by a Touhy Borst valve 8. This prevents any sliding movement between the shaft and sheath which could result in a premature deployment or partial deployment of the slant.
When the slant 50 reaches its target site and is ready for deployment, the Tou6y Borst valve 8 is opened so that that the sheath 40 and shaft 10 are no longer locked together.
The method under which apparatus 1 deploys slant 50 should be readily apparent. The apparatus 1 is first inserted into a vessel so that the slant bed 24 is at a target diseased site. Once this has occurred the physician would open the Touhy Borst valve 8. The physician would then grasp the proximal end 12 of shaft 10 so as to hold it in place. Thereafter, the physician would grasp the pmxirnal end 42 of sheath 40 and slide it proximal, relative to the shaft 40. Stop 22 prevents the slant 50 from sliding back with the sheath 40, so that as the sheath 40 is moved back, the slant SO is pushed out of the distal end 44 of fhe sheath 40. Stent deployment is complete when the radiopaque band 46 on the sheath 40 is proximal to radiopaque stop 22. The apparatus 1 can now be withdrawn through slant 50 and removed from the patient.
Although particular embodiments of the present invention have been shown and described, modification may be made to the device and/or method without departing from the spirit and scope of the present invention. The terms used in describing the invention are used in their descriptive sense and not as terms of limitations.
THAT WHICH IS CLAI1VVIED IS:
Claims (15)
1. A stent for insertion into a vessel of a patient, said stent comprising;
a) a tubular member having a thickness and having front and back open ends and a longitudinal axis extending therebetween, said member having a first smaller diameter for insertion into said vessel, and a second larger diameter for deployment into said vessel;
b) said tubular member comprising a plurality of adjacent hoops extending between said front and back ends, said hoops comprising a plurality of longitudinal struts and a plurality of loops connecting adjacent struts, said member further comprising a plurality of bridges connecting adjacent hoops to one another; and c) wherein said struts have lengths, measured parallel to said longitudinal axis, and wherein the ratio of the number of struts per hoop to the length of a strut as measured in inches is greater than about 400.
a) a tubular member having a thickness and having front and back open ends and a longitudinal axis extending therebetween, said member having a first smaller diameter for insertion into said vessel, and a second larger diameter for deployment into said vessel;
b) said tubular member comprising a plurality of adjacent hoops extending between said front and back ends, said hoops comprising a plurality of longitudinal struts and a plurality of loops connecting adjacent struts, said member further comprising a plurality of bridges connecting adjacent hoops to one another; and c) wherein said struts have lengths, measured parallel to said longitudinal axis, and wherein the ratio of the number of struts per hoop to the length of a strut as measured in inches is greater than about 400.
2. The stent according to claim 1 wherein said loops comprise curved substantially semi-circular sections having centers, said bridges being connected to said loops at loop to bridge connection points having centers, said centers of said points are offset from said centers of said loops.
3. The stent according to claim 1 wherein said stent is made from a superelastic alloy.
4. The stent according to claim 3 wherein said alloy comprises from about 50.5 percent to about 60 percent Nickel and the remainder comprising Titanium.
5. The stent according to claim 1 wherein said bridges and struts have widths which are less than said thickness of said tubular member.
6. The stent according to claim 2 wherein said bridges are curved.
7. The stent according to claim 6 wherein bridges which connect a first and second hoop together are curved in an opposite direction as bridges which connect a second a third hoop together.
8. The stent according to claim 1 wherein said loops and struts have thicknesses, and wherein the thickness of said loop is Beater than said thickness of said strut.
9. A stent for insertion into a vessel of a patient, said stent comprising;
a) a tubular member, made from a super-elastic Nickel Titanium alloy, having a thickness and having front and back open ends and a longitudinal axis extending therebetween, said member having a first smaller diameter for insertion into said vessel, and a second larger diameter for deployment into said vessel;
b) said tubular member comprising a plurality of adjacent hoops extending between said front and back ends, said hoops comprising a plurality of longitudinal struts and a plurality of loops connecting adjacent struts, said member further comprising a plurality of bridges connecting adjacent hoops to one another; and c) wherein said struts have lengths, measured parallel to said longitudinal axis, and wherein the ratio of the number of struts per hoop to the length of a strut as measured in inches is greater than about 400.
a) a tubular member, made from a super-elastic Nickel Titanium alloy, having a thickness and having front and back open ends and a longitudinal axis extending therebetween, said member having a first smaller diameter for insertion into said vessel, and a second larger diameter for deployment into said vessel;
b) said tubular member comprising a plurality of adjacent hoops extending between said front and back ends, said hoops comprising a plurality of longitudinal struts and a plurality of loops connecting adjacent struts, said member further comprising a plurality of bridges connecting adjacent hoops to one another; and c) wherein said struts have lengths, measured parallel to said longitudinal axis, and wherein the ratio of the number of struts per hoop to the length of a strut as measured in inches is greater than about 400.
10. The stent according to claim 9 wherein said loops comprise curved substantially semi-circular sections having centers, said bridges being connected to said loops at loop to bridge connection points having centers, said centers of said points are offset from said centers of said loops.
11. The stent according to claim 9 wherein said alloy comprises from about 50.5 percent to about 60 percent Nickel and the remainder comprising Titanium.
12. The stent according to claim 9 wherein said bridges and struts have widths which are less than said thickness of said tubular member.
13. The stent according to claim 10 wherein said bridges are curved.
14. The stent according to claim 13 wherein bridges which connect a first and second hoop together are curved in an opposite direction as bridges which connect a second a third hoop together.
15. The stent according to claim 9 wherein said loops and struts have thicknesses, and wherein the thickness of said loop is greater than said thickness of said strut.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/005,401 | 1998-01-09 | ||
US09/005,401 US6129755A (en) | 1998-01-09 | 1998-01-09 | Intravascular stent having an improved strut configuration |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2257751A1 CA2257751A1 (en) | 1999-07-09 |
CA2257751C true CA2257751C (en) | 2006-08-01 |
Family
ID=21715665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002257751A Expired - Lifetime CA2257751C (en) | 1998-01-09 | 1999-01-04 | An intravascular stent having an improved strut configuration |
Country Status (7)
Country | Link |
---|---|
US (1) | US6129755A (en) |
EP (1) | EP0928605B1 (en) |
JP (1) | JP4703798B2 (en) |
AU (1) | AU740593B2 (en) |
CA (1) | CA2257751C (en) |
DE (1) | DE69915895T2 (en) |
ES (1) | ES2217689T3 (en) |
Families Citing this family (230)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69637527D1 (en) * | 1995-03-01 | 2008-06-26 | Boston Scient Scimed Inc | Longitudinally flexible and expandable stent |
US6896696B2 (en) | 1998-11-20 | 2005-05-24 | Scimed Life Systems, Inc. | Flexible and expandable stent |
US7204848B1 (en) | 1995-03-01 | 2007-04-17 | Boston Scientific Scimed, Inc. | Longitudinally flexible expandable stent |
JP4636634B2 (en) | 1996-04-26 | 2011-02-23 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Intravascular stent |
US20040106985A1 (en) | 1996-04-26 | 2004-06-03 | Jang G. David | Intravascular stent |
US6235053B1 (en) | 1998-02-02 | 2001-05-22 | G. David Jang | Tubular stent consists of chevron-shape expansion struts and contralaterally attached diagonal connectors |
EP0884029B1 (en) * | 1997-06-13 | 2004-12-22 | Gary J. Becker | Expandable intraluminal endoprosthesis |
DE59711236D1 (en) * | 1997-06-30 | 2004-02-26 | Medex Holding Gmbh | Intraluminal implant |
US6330884B1 (en) * | 1997-11-14 | 2001-12-18 | Transvascular, Inc. | Deformable scaffolding multicellular stent |
US6503271B2 (en) * | 1998-01-09 | 2003-01-07 | Cordis Corporation | Intravascular device with improved radiopacity |
US6264687B1 (en) * | 1998-04-20 | 2001-07-24 | Cordis Corporation | Multi-laminate stent having superelastic articulated sections |
US7815763B2 (en) | 2001-09-28 | 2010-10-19 | Abbott Laboratories Vascular Enterprises Limited | Porous membranes for medical implants and methods of manufacture |
US6682554B2 (en) | 1998-09-05 | 2004-01-27 | Jomed Gmbh | Methods and apparatus for a stent having an expandable web structure |
DE19840645A1 (en) * | 1998-09-05 | 2000-03-09 | Jomed Implantate Gmbh | Stent |
US7887578B2 (en) | 1998-09-05 | 2011-02-15 | Abbott Laboratories Vascular Enterprises Limited | Stent having an expandable web structure |
US6755856B2 (en) | 1998-09-05 | 2004-06-29 | Abbott Laboratories Vascular Enterprises Limited | Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
US6325820B1 (en) * | 1998-11-16 | 2001-12-04 | Endotex Interventional Systems, Inc. | Coiled-sheet stent-graft with exo-skeleton |
US6743252B1 (en) * | 1998-12-18 | 2004-06-01 | Cook Incorporated | Cannula stent |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6425855B2 (en) * | 1999-04-06 | 2002-07-30 | Cordis Corporation | Method for making a multi-laminate stent having superelastic articulated sections |
EP1173110B1 (en) | 1999-04-15 | 2009-07-08 | Smart Therapeutics, Inc. | Intravascular stent for treating neurovascular vessel lesion |
US6899730B1 (en) | 1999-04-15 | 2005-05-31 | Scimed Life Systems, Inc. | Catheter-stent device |
US6939361B1 (en) | 1999-09-22 | 2005-09-06 | Nmt Medical, Inc. | Guidewire for a free standing intervascular device having an integral stop mechanism |
US6296661B1 (en) * | 2000-02-01 | 2001-10-02 | Luis A. Davila | Self-expanding stent-graft |
US6245100B1 (en) * | 2000-02-01 | 2001-06-12 | Cordis Corporation | Method for making a self-expanding stent-graft |
EP1132058A1 (en) * | 2000-03-06 | 2001-09-12 | Advanced Laser Applications Holding S.A. | Intravascular prothesis |
US6616689B1 (en) | 2000-05-03 | 2003-09-09 | Advanced Cardiovascular Systems, Inc. | Intravascular stent |
US6585765B1 (en) * | 2000-06-29 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Implantable device having substances impregnated therein and a method of impregnating the same |
US6740061B1 (en) | 2000-07-28 | 2004-05-25 | Ev3 Inc. | Distal protection device |
DE10044043A1 (en) * | 2000-08-30 | 2002-03-14 | Biotronik Mess & Therapieg | Repositionable stent |
GB0022097D0 (en) * | 2000-09-08 | 2000-10-25 | Cathnet Science S A | Expandable stent |
US8070792B2 (en) | 2000-09-22 | 2011-12-06 | Boston Scientific Scimed, Inc. | Stent |
US7766956B2 (en) | 2000-09-22 | 2010-08-03 | Boston Scientific Scimed, Inc. | Intravascular stent and assembly |
US6863685B2 (en) * | 2001-03-29 | 2005-03-08 | Cordis Corporation | Radiopacity intraluminal medical device |
CA2424029C (en) | 2000-09-29 | 2008-01-29 | Cordis Corporation | Coated medical devices |
DE10050971A1 (en) * | 2000-10-10 | 2002-04-11 | Biotronik Mess & Therapieg | stent |
US7037330B1 (en) * | 2000-10-16 | 2006-05-02 | Scimed Life Systems, Inc. | Neurovascular stent and method |
US6758859B1 (en) * | 2000-10-30 | 2004-07-06 | Kenny L. Dang | Increased drug-loading and reduced stress drug delivery device |
US6929660B1 (en) | 2000-12-22 | 2005-08-16 | Advanced Cardiovascular Systems, Inc. | Intravascular stent |
US8038708B2 (en) | 2001-02-05 | 2011-10-18 | Cook Medical Technologies Llc | Implantable device with remodelable material and covering material |
US20050021123A1 (en) | 2001-04-30 | 2005-01-27 | Jurgen Dorn | Variable speed self-expanding stent delivery system and luer locking connector |
US6676702B2 (en) * | 2001-05-14 | 2004-01-13 | Cardiac Dimensions, Inc. | Mitral valve therapy assembly and method |
US6800090B2 (en) * | 2001-05-14 | 2004-10-05 | Cardiac Dimensions, Inc. | Mitral valve therapy device, system and method |
US6562067B2 (en) * | 2001-06-08 | 2003-05-13 | Cordis Corporation | Stent with interlocking elements |
US6939373B2 (en) | 2003-08-20 | 2005-09-06 | Advanced Cardiovascular Systems, Inc. | Intravascular stent |
US6629994B2 (en) * | 2001-06-11 | 2003-10-07 | Advanced Cardiovascular Systems, Inc. | Intravascular stent |
US8197535B2 (en) * | 2001-06-19 | 2012-06-12 | Cordis Corporation | Low profile improved radiopacity intraluminal medical device |
US6635083B1 (en) | 2001-06-25 | 2003-10-21 | Advanced Cardiovascular Systems, Inc. | Stent with non-linear links and method of use |
US6749629B1 (en) | 2001-06-27 | 2004-06-15 | Advanced Cardiovascular Systems, Inc. | Stent pattern with figure-eights |
US6695920B1 (en) | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US6605110B2 (en) * | 2001-06-29 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Stent with enhanced bendability and flexibility |
WO2003022344A2 (en) | 2001-09-06 | 2003-03-20 | Nmt Medical, Inc. | Flexible delivery system |
US20030055485A1 (en) | 2001-09-17 | 2003-03-20 | Intra Therapeutics, Inc. | Stent with offset cell geometry |
US7175655B1 (en) * | 2001-09-17 | 2007-02-13 | Endovascular Technologies, Inc. | Avoiding stress-induced martensitic transformation in nickel titanium alloys used in medical devices |
US6949122B2 (en) * | 2001-11-01 | 2005-09-27 | Cardiac Dimensions, Inc. | Focused compression mitral valve device and method |
US7635387B2 (en) | 2001-11-01 | 2009-12-22 | Cardiac Dimensions, Inc. | Adjustable height focal tissue deflector |
US6824562B2 (en) | 2002-05-08 | 2004-11-30 | Cardiac Dimensions, Inc. | Body lumen device anchor, device and assembly |
US7311729B2 (en) | 2002-01-30 | 2007-12-25 | Cardiac Dimensions, Inc. | Device and method for modifying the shape of a body organ |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US7682387B2 (en) * | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US6793673B2 (en) | 2002-12-26 | 2004-09-21 | Cardiac Dimensions, Inc. | System and method to effect mitral valve annulus of a heart |
US6976995B2 (en) | 2002-01-30 | 2005-12-20 | Cardiac Dimensions, Inc. | Fixed length anchor and pull mitral valve device and method |
US7179282B2 (en) | 2001-12-05 | 2007-02-20 | Cardiac Dimensions, Inc. | Device and method for modifying the shape of a body organ |
US6908478B2 (en) | 2001-12-05 | 2005-06-21 | Cardiac Dimensions, Inc. | Anchor and pull mitral valve device and method |
US20050182477A1 (en) * | 2001-12-20 | 2005-08-18 | White Geoffrey H. | Intraluminal stent and graft |
US6960229B2 (en) * | 2002-01-30 | 2005-11-01 | Cardiac Dimensions, Inc. | Device and method for modifying the shape of a body organ |
US7004958B2 (en) * | 2002-03-06 | 2006-02-28 | Cardiac Dimensions, Inc. | Transvenous staples, assembly and method for mitral valve repair |
US6797001B2 (en) | 2002-03-11 | 2004-09-28 | Cardiac Dimensions, Inc. | Device, assembly and method for mitral valve repair |
US20040024450A1 (en) * | 2002-04-24 | 2004-02-05 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
CA2950492C (en) | 2002-05-08 | 2018-12-04 | Cardiac Dimensions Pty. Ltd. | Device and method for modifying the shape of a body organ |
US6656220B1 (en) | 2002-06-17 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Intravascular stent |
US8080052B2 (en) * | 2002-06-28 | 2011-12-20 | Cordis Corporation | Stent with diagonal flexible connecting links |
DE10233085B4 (en) | 2002-07-19 | 2014-02-20 | Dendron Gmbh | Stent with guide wire |
US8425549B2 (en) | 2002-07-23 | 2013-04-23 | Reverse Medical Corporation | Systems and methods for removing obstructive matter from body lumens and treating vascular defects |
US6969402B2 (en) * | 2002-07-26 | 2005-11-29 | Syntheon, Llc | Helical stent having flexible transition zone |
US6878162B2 (en) * | 2002-08-30 | 2005-04-12 | Edwards Lifesciences Ag | Helical stent having improved flexibility and expandability |
US9561123B2 (en) | 2002-08-30 | 2017-02-07 | C.R. Bard, Inc. | Highly flexible stent and method of manufacture |
DE10243136A1 (en) * | 2002-09-17 | 2004-05-19 | Campus Medizin & Technik Gmbh | Stent for implantation in or around a hollow organ |
US7135038B1 (en) * | 2002-09-30 | 2006-11-14 | Advanced Cardiovascular Systems, Inc. | Drug eluting stent |
US6814746B2 (en) * | 2002-11-01 | 2004-11-09 | Ev3 Peripheral, Inc. | Implant delivery system with marker interlock |
US7316708B2 (en) | 2002-12-05 | 2008-01-08 | Cardiac Dimensions, Inc. | Medical device delivery system |
US7837729B2 (en) | 2002-12-05 | 2010-11-23 | Cardiac Dimensions, Inc. | Percutaneous mitral valve annuloplasty delivery system |
US7074276B1 (en) | 2002-12-12 | 2006-07-11 | Advanced Cardiovascular Systems, Inc. | Clamp mandrel fixture and a method of using the same to minimize coating defects |
US7314485B2 (en) | 2003-02-03 | 2008-01-01 | Cardiac Dimensions, Inc. | Mitral valve device using conditioned shape memory alloy |
US7763045B2 (en) | 2003-02-11 | 2010-07-27 | Cook Incorporated | Removable vena cava filter |
US20050131524A1 (en) * | 2003-02-25 | 2005-06-16 | Majercak David C. | Method for treating a bifurcated vessel |
US7918884B2 (en) * | 2003-02-25 | 2011-04-05 | Cordis Corporation | Stent for treatment of bifurcated lesions |
US7942920B2 (en) * | 2003-02-25 | 2011-05-17 | Cordis Corporation | Stent with nested fingers for enhanced vessel coverage |
US20080051866A1 (en) * | 2003-02-26 | 2008-02-28 | Chao Chin Chen | Drug delivery devices and methods |
US20040167610A1 (en) * | 2003-02-26 | 2004-08-26 | Fleming James A. | Locking stent |
US20040249442A1 (en) * | 2003-02-26 | 2004-12-09 | Fleming James A. | Locking stent having multiple locking points |
US20040176788A1 (en) * | 2003-03-07 | 2004-09-09 | Nmt Medical, Inc. | Vacuum attachment system |
US7658747B2 (en) | 2003-03-12 | 2010-02-09 | Nmt Medical, Inc. | Medical device for manipulation of a medical implant |
US7473266B2 (en) | 2003-03-14 | 2009-01-06 | Nmt Medical, Inc. | Collet-based delivery system |
JP5021298B2 (en) | 2003-03-19 | 2012-09-05 | アドヴァンスド バイオ プロスセティック サーフェシーズ リミテッド | Lumen stent with intermediate strut interconnection member |
WO2004091449A1 (en) * | 2003-04-08 | 2004-10-28 | Cook Incorporated | Intraluminal support device with graft |
US7625399B2 (en) * | 2003-04-24 | 2009-12-01 | Cook Incorporated | Intralumenally-implantable frames |
US7658759B2 (en) * | 2003-04-24 | 2010-02-09 | Cook Incorporated | Intralumenally implantable frames |
US7717952B2 (en) | 2003-04-24 | 2010-05-18 | Cook Incorporated | Artificial prostheses with preferred geometries |
US8221492B2 (en) | 2003-04-24 | 2012-07-17 | Cook Medical Technologies | Artificial valve prosthesis with improved flow dynamics |
US20040220654A1 (en) | 2003-05-02 | 2004-11-04 | Cardiac Dimensions, Inc. | Device and method for modifying the shape of a body organ |
US7789979B2 (en) * | 2003-05-02 | 2010-09-07 | Gore Enterprise Holdings, Inc. | Shape memory alloy articles with improved fatigue performance and methods therefor |
US7323209B1 (en) | 2003-05-15 | 2008-01-29 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for coating stents |
US7887582B2 (en) | 2003-06-05 | 2011-02-15 | Cardiac Dimensions, Inc. | Device and method for modifying the shape of a body organ |
US7351259B2 (en) | 2003-06-05 | 2008-04-01 | Cardiac Dimensions, Inc. | Device, system and method to affect the mitral valve annulus of a heart |
CA2538476A1 (en) | 2003-09-11 | 2005-04-21 | Nmt Medical, Inc. | Devices, systems, and methods for suturing tissue |
WO2005046487A1 (en) | 2003-11-06 | 2005-05-26 | Nmt Medical, Inc. | Transseptal puncture apparatus |
US8292910B2 (en) | 2003-11-06 | 2012-10-23 | Pressure Products Medical Supplies, Inc. | Transseptal puncture apparatus |
US7056286B2 (en) | 2003-11-12 | 2006-06-06 | Adrian Ravenscroft | Medical device anchor and delivery system |
US9526616B2 (en) | 2003-12-19 | 2016-12-27 | Cardiac Dimensions Pty. Ltd. | Mitral valve annuloplasty device with twisted anchor |
US7794496B2 (en) | 2003-12-19 | 2010-09-14 | Cardiac Dimensions, Inc. | Tissue shaping device with integral connector and crimp |
US7837728B2 (en) | 2003-12-19 | 2010-11-23 | Cardiac Dimensions, Inc. | Reduced length tissue shaping device |
EP1713401A2 (en) | 2004-01-30 | 2006-10-25 | NMT Medical, Inc. | Devices, systems, and methods for closure of cardiac openings |
ATE503438T1 (en) | 2004-04-16 | 2011-04-15 | Cook Inc | REMOVABLE VENA CAVA FILTER TO REDUCE TRAUMA IN FOLDED STATE |
JP4898988B2 (en) | 2004-04-16 | 2012-03-21 | クック メディカル テクノロジーズ エルエルシー | Retrievable vena cava filter with primary struts to enhance retrieval and delivery performance |
US8043322B2 (en) | 2004-04-16 | 2011-10-25 | Cook Medical Technologies Llc | Removable vena cava filter having inwardly positioned anchoring hooks in collapsed configuration |
DE602005025329D1 (en) | 2004-04-16 | 2011-01-27 | Cook William Europ | REMOVABLE VENA CAVA FILTER WITH ANCHORAGE DEVICE FOR REDUCED TRAUMATA |
US20050261757A1 (en) * | 2004-05-21 | 2005-11-24 | Conor Medsystems, Inc. | Stent with contoured bridging element |
US20050273151A1 (en) * | 2004-06-04 | 2005-12-08 | John Fulkerson | Stent delivery system |
US20060064155A1 (en) * | 2004-09-01 | 2006-03-23 | Pst, Llc | Stent and method for manufacturing the stent |
US20060074480A1 (en) | 2004-09-01 | 2006-04-06 | Pst, Llc | Stent and method for manufacturing the stent |
US7901451B2 (en) | 2004-09-24 | 2011-03-08 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
JP2008514293A (en) | 2004-09-27 | 2008-05-08 | クック インコーポレイテッド | Removable vena cava filter with struts with axial curvature |
DE102004055583A1 (en) * | 2004-11-18 | 2006-05-24 | Bkh - Technotransfer Gmbh | Marker e.g. for animal and human tissue, tumor identification, is circularly manufactured by predetermined material such as Nickel titanium wire, and longitudinally extended to form ring |
CA2595580A1 (en) | 2005-01-20 | 2006-07-27 | Cardiac Dimensions, Inc. | Tissue shaping device |
FR2881946B1 (en) | 2005-02-17 | 2008-01-04 | Jacques Seguin | DEVICE FOR THE TREATMENT OF BODILY CONDUIT AT BIFURCATION LEVEL |
US8002818B2 (en) * | 2005-02-25 | 2011-08-23 | Abbott Laboratories Vascular Enterprises Limited | Modular vascular prosthesis having axially variable properties and improved flexibility and methods of use |
US8025694B2 (en) * | 2005-02-25 | 2011-09-27 | Abbott Laboratories Vascular Enterprises Limited | Modular vascular prosthesis and methods of use |
US8652193B2 (en) | 2005-05-09 | 2014-02-18 | Angiomed Gmbh & Co. Medizintechnik Kg | Implant delivery device |
US7823533B2 (en) | 2005-06-30 | 2010-11-02 | Advanced Cardiovascular Systems, Inc. | Stent fixture and method for reducing coating defects |
AU2006270221B2 (en) | 2005-07-15 | 2012-01-19 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
US7735449B1 (en) | 2005-07-28 | 2010-06-15 | Advanced Cardiovascular Systems, Inc. | Stent fixture having rounded support structures and method for use thereof |
EP2179709B1 (en) | 2005-08-17 | 2011-10-05 | C. R. Bard, Inc. | Variable speed stent delivery system |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US11026822B2 (en) | 2006-01-13 | 2021-06-08 | C. R. Bard, Inc. | Stent delivery system |
EP2727564B1 (en) | 2006-01-13 | 2023-05-03 | C. R. Bard, Inc. | Stent delivery system |
US9456911B2 (en) * | 2006-02-14 | 2016-10-04 | Angiomed Gmbh & Co. Medizintechnik | Highly flexible stent and method of manufacture |
US7503932B2 (en) | 2006-04-11 | 2009-03-17 | Cardiac Dimensions, Inc. | Mitral valve annuloplasty device with vena cava anchor |
EP2019657B1 (en) | 2006-04-26 | 2015-05-27 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US7985441B1 (en) | 2006-05-04 | 2011-07-26 | Yiwen Tang | Purification of polymers for coating applications |
US8069814B2 (en) | 2006-05-04 | 2011-12-06 | Advanced Cardiovascular Systems, Inc. | Stent support devices |
US7717892B2 (en) | 2006-07-10 | 2010-05-18 | Mcneil-Ppc, Inc. | Method of treating urinary incontinence |
US10219884B2 (en) | 2006-07-10 | 2019-03-05 | First Quality Hygienic, Inc. | Resilient device |
US10004584B2 (en) | 2006-07-10 | 2018-06-26 | First Quality Hygienic, Inc. | Resilient intravaginal device |
BRPI0714288B1 (en) | 2006-07-10 | 2018-06-26 | Mcneil-Ppc, Inc. | INTRAVAGINAL URINARY INCONTINENCE DEVICE |
US8613698B2 (en) | 2006-07-10 | 2013-12-24 | Mcneil-Ppc, Inc. | Resilient device |
US11285005B2 (en) | 2006-07-17 | 2022-03-29 | Cardiac Dimensions Pty. Ltd. | Mitral valve annuloplasty device with twisted anchor |
GB0615658D0 (en) | 2006-08-07 | 2006-09-13 | Angiomed Ag | Hand-held actuator device |
US7988720B2 (en) | 2006-09-12 | 2011-08-02 | Boston Scientific Scimed, Inc. | Longitudinally flexible expandable stent |
US8778009B2 (en) | 2006-10-06 | 2014-07-15 | Abbott Cardiovascular Systems Inc. | Intravascular stent |
US20080097591A1 (en) * | 2006-10-20 | 2008-04-24 | Biosensors International Group | Drug-delivery endovascular stent and method of use |
US8067055B2 (en) * | 2006-10-20 | 2011-11-29 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method of use |
US9539593B2 (en) | 2006-10-23 | 2017-01-10 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
US20080269774A1 (en) | 2006-10-26 | 2008-10-30 | Chestnut Medical Technologies, Inc. | Intracorporeal Grasping Device |
JP5078346B2 (en) | 2006-12-28 | 2012-11-21 | テルモ株式会社 | Self-expanding stent |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
EP2111184B1 (en) | 2007-01-08 | 2018-07-25 | Micell Technologies, Inc. | Stents having biodegradable layers |
FR2911063B1 (en) | 2007-01-09 | 2009-03-20 | Stentys S A S Soc Par Actions | RUPTIBLE BRIDGE STRUCTURE FOR STENT, AND STENT INCLUDING SUCH BRIDGE STRUCTURES. |
EP2120785B1 (en) * | 2007-02-12 | 2021-12-01 | C.R. Bard, Inc. | Highly flexible stent and method of manufacture |
US8333799B2 (en) | 2007-02-12 | 2012-12-18 | C. R. Bard, Inc. | Highly flexible stent and method of manufacture |
US8974514B2 (en) * | 2007-03-13 | 2015-03-10 | Abbott Cardiovascular Systems Inc. | Intravascular stent with integrated link and ring strut |
DE102007019772B4 (en) | 2007-04-26 | 2019-09-26 | Acandis Gmbh | Stent and method of making a stent |
US8128679B2 (en) | 2007-05-23 | 2012-03-06 | Abbott Laboratories Vascular Enterprises Limited | Flexible stent with torque-absorbing connectors |
US8016874B2 (en) | 2007-05-23 | 2011-09-13 | Abbott Laboratories Vascular Enterprises Limited | Flexible stent with elevated scaffolding properties |
CA2688314C (en) | 2007-05-25 | 2013-12-03 | Micell Technologies, Inc. | Polymer films for medical device coating |
GB0713497D0 (en) | 2007-07-11 | 2007-08-22 | Angiomed Ag | Device for catheter sheath retraction |
US9144508B2 (en) * | 2007-07-19 | 2015-09-29 | Back Bay Medical Inc. | Radially expandable stent |
US8252035B2 (en) * | 2007-08-01 | 2012-08-28 | Cappella, Inc. | Device delivery system with two stage withdrawal |
KR100930167B1 (en) * | 2007-09-19 | 2009-12-07 | 삼성전기주식회사 | Ultra wide angle optical system |
US11337714B2 (en) | 2007-10-17 | 2022-05-24 | Covidien Lp | Restoring blood flow and clot removal during acute ischemic stroke |
US8088140B2 (en) | 2008-05-19 | 2012-01-03 | Mindframe, Inc. | Blood flow restorative and embolus removal methods |
WO2009051780A1 (en) * | 2007-10-19 | 2009-04-23 | Micell Technologies, Inc. | Drug coated stents |
US7850726B2 (en) | 2007-12-20 | 2010-12-14 | Abbott Laboratories Vascular Enterprises Limited | Endoprosthesis having struts linked by foot extensions |
US8920488B2 (en) | 2007-12-20 | 2014-12-30 | Abbott Laboratories Vascular Enterprises Limited | Endoprosthesis having a stable architecture |
US8337544B2 (en) | 2007-12-20 | 2012-12-25 | Abbott Laboratories Vascular Enterprises Limited | Endoprosthesis having flexible connectors |
US8246672B2 (en) | 2007-12-27 | 2012-08-21 | Cook Medical Technologies Llc | Endovascular graft with separately positionable and removable frame units |
US8091455B2 (en) | 2008-01-30 | 2012-01-10 | Cummins Filtration Ip, Inc. | Apparatus, system, and method for cutting tubes |
US8940003B2 (en) | 2008-02-22 | 2015-01-27 | Covidien Lp | Methods and apparatus for flow restoration |
MX350637B (en) | 2008-04-17 | 2017-09-11 | Micell Technologies Inc | Stents having bioabsorbable layers. |
WO2010009335A1 (en) | 2008-07-17 | 2010-01-21 | Micell Technologies, Inc. | Drug delivery medical device |
US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
US9005274B2 (en) | 2008-08-04 | 2015-04-14 | Stentys Sas | Method for treating a body lumen |
US8006594B2 (en) | 2008-08-11 | 2011-08-30 | Cardiac Dimensions, Inc. | Catheter cutting tool |
CN101732114B (en) * | 2008-11-04 | 2014-07-30 | 上海微创医疗器械(集团)有限公司 | Coronary artery stent with medicine carrying grooves |
US8246648B2 (en) | 2008-11-10 | 2012-08-21 | Cook Medical Technologies Llc | Removable vena cava filter with improved leg |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
CN102481195B (en) | 2009-04-01 | 2015-03-25 | 米歇尔技术公司 | Drug delivery medical device |
CA2759015C (en) | 2009-04-17 | 2017-06-20 | James B. Mcclain | Stents having controlled elution |
EP2493430B1 (en) * | 2009-10-30 | 2020-12-02 | Cardinal Health Switzerland 515 GmbH | Intraluminal device with improved flexibility and durability |
EP2496189A4 (en) | 2009-11-04 | 2016-05-11 | Nitinol Devices And Components Inc | Alternating circumferential bridge stent design and methods for use thereof |
WO2011097103A1 (en) | 2010-02-02 | 2011-08-11 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
WO2011133655A1 (en) | 2010-04-22 | 2011-10-27 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
US9301864B2 (en) | 2010-06-08 | 2016-04-05 | Veniti, Inc. | Bi-directional stent delivery system |
US8864811B2 (en) | 2010-06-08 | 2014-10-21 | Veniti, Inc. | Bi-directional stent delivery system |
US20130172853A1 (en) | 2010-07-16 | 2013-07-04 | Micell Technologies, Inc. | Drug delivery medical device |
US9233014B2 (en) | 2010-09-24 | 2016-01-12 | Veniti, Inc. | Stent with support braces |
US9039749B2 (en) | 2010-10-01 | 2015-05-26 | Covidien Lp | Methods and apparatuses for flow restoration and implanting members in the human body |
EP2624791B1 (en) | 2010-10-08 | 2017-06-21 | Confluent Medical Technologies, Inc. | Alternating circumferential bridge stent design |
GB201017834D0 (en) | 2010-10-21 | 2010-12-01 | Angiomed Ag | System to deliver a bodily implant |
WO2012060225A1 (en) * | 2010-11-01 | 2012-05-10 | テルモ株式会社 | Composite |
EP2658484A1 (en) | 2010-12-30 | 2013-11-06 | Boston Scientific Scimed, Inc. | Multi stage opening stent designs |
US10022212B2 (en) | 2011-01-13 | 2018-07-17 | Cook Medical Technologies Llc | Temporary venous filter with anti-coagulant delivery method |
EP2680797B1 (en) | 2011-03-03 | 2016-10-26 | Boston Scientific Scimed, Inc. | Low strain high strength stent |
WO2012119037A1 (en) | 2011-03-03 | 2012-09-07 | Boston Scientific Scimed, Inc. | Stent with reduced profile |
US9028540B2 (en) | 2011-03-25 | 2015-05-12 | Covidien Lp | Vascular stent with improved vessel wall apposition |
WO2012166819A1 (en) | 2011-05-31 | 2012-12-06 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
CA2841360A1 (en) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
RU2502482C2 (en) * | 2011-12-19 | 2013-12-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Национальный исследовательский технологический университет "МИСиС" | Method of surgical treatment of intestinal obstruction of small and large intestine and device for its realisation |
EP2811939B8 (en) | 2012-02-10 | 2017-11-15 | CVDevices, LLC | Products made of biological tissues for stents and methods of manufacturing |
US9821145B2 (en) | 2012-03-23 | 2017-11-21 | Pressure Products Medical Supplies Inc. | Transseptal puncture apparatus and method for using the same |
US9066825B2 (en) | 2012-05-14 | 2015-06-30 | C.R. Bard, Inc. | Uniformly expandable stent |
US9254205B2 (en) | 2012-09-27 | 2016-02-09 | Covidien Lp | Vascular stent with improved vessel wall apposition |
WO2014110209A1 (en) * | 2013-01-09 | 2014-07-17 | Cook Medical Technologies Llc | Abdominal retractor |
US20140228937A1 (en) | 2013-02-11 | 2014-08-14 | Joshua Krieger | Expandable Support Frame and Medical Device |
USD723165S1 (en) | 2013-03-12 | 2015-02-24 | C. R. Bard, Inc. | Stent |
CN110269959A (en) | 2013-03-12 | 2019-09-24 | 脉胜医疗技术公司 | Bioabsorbable biomedical implants |
JP6055955B2 (en) * | 2013-04-24 | 2016-12-27 | バスキュラー ダイナミクス, インコーポレイテッド | Implantable vascular device with longitudinal struts |
US10272606B2 (en) | 2013-05-15 | 2019-04-30 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
JP6373831B2 (en) | 2013-05-23 | 2018-08-15 | 学校法人東海大学 | Stent |
US10076399B2 (en) | 2013-09-13 | 2018-09-18 | Covidien Lp | Endovascular device engagement |
EP3294160B1 (en) * | 2015-05-14 | 2022-04-20 | Cook Medical Technologies, LLC | Endoscopic needle stylet with enhanced-flexibility lengths |
CN108289748B (en) * | 2015-11-18 | 2020-08-11 | 百乐仕医疗器械有限公司 | Support frame |
US10390953B2 (en) | 2017-03-08 | 2019-08-27 | Cardiac Dimensions Pty. Ltd. | Methods and devices for reducing paravalvular leakage |
US10238513B2 (en) | 2017-07-19 | 2019-03-26 | Abbott Cardiovascular Systems Inc. | Intravascular stent |
WO2020191203A1 (en) | 2019-03-20 | 2020-09-24 | inQB8 Medical Technologies, LLC | Aortic dissection implant |
JP2023554000A (en) | 2020-12-14 | 2023-12-26 | カーディアック・ディメンションズ・プロプライエタリー・リミテッド | Modular preloaded medical implants and delivery systems |
US11844893B2 (en) | 2021-01-17 | 2023-12-19 | Inspire M.D Ltd. | Shunts with blood-flow indicators |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3585707A (en) * | 1966-04-13 | 1971-06-22 | Cordis Corp | Method of making tubular products |
SE445884B (en) * | 1982-04-30 | 1986-07-28 | Medinvent Sa | DEVICE FOR IMPLANTATION OF A RODFORM PROTECTION |
CA1232814A (en) * | 1983-09-16 | 1988-02-16 | Hidetoshi Sakamoto | Guide wire for catheter |
US4665906A (en) * | 1983-10-14 | 1987-05-19 | Raychem Corporation | Medical devices incorporating sim alloy elements |
US4665771A (en) | 1984-10-15 | 1987-05-19 | Mitchell Frank R | Hypocyclic drive |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4665905A (en) | 1986-06-09 | 1987-05-19 | Brown Charles S | Dynamic elbow and knee extension brace |
US5045072A (en) * | 1989-06-13 | 1991-09-03 | Cordis Corporation | Catheter having highly radiopaque, flexible tip |
US5254107A (en) * | 1991-03-06 | 1993-10-19 | Cordis Corporation | Catheter having extended braid reinforced transitional tip |
US5683411A (en) * | 1994-04-06 | 1997-11-04 | William Cook Europe A/S | Medical article for implantation into the vascular system of a patient |
DE69637527D1 (en) * | 1995-03-01 | 2008-06-26 | Boston Scient Scimed Inc | Longitudinally flexible and expandable stent |
WO1997000294A1 (en) * | 1995-06-19 | 1997-01-03 | Shell Internationale Research Maatschappij B.V. | Free flowing powder composition |
RU2172074C2 (en) * | 1995-08-03 | 2001-08-10 | Нортерн Телеком Лимитед | Process of synchronization of pseudorandom numerical sequence with indetermination of sign in communication system |
WO1997006611A1 (en) * | 1995-08-03 | 1997-02-20 | Telefonaktiebolaget Lm Ericsson (Publ) | A wireless multi-cell radio telecommunication system |
GB9516158D0 (en) * | 1995-08-07 | 1995-10-04 | Stc Submarine Systems Ltd | Switching control circuit for branching units |
AUPN483395A0 (en) * | 1995-08-16 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Die casting devices |
GB9517055D0 (en) * | 1995-08-19 | 1995-10-25 | Normalair Garrett Ltd | Apparatus and method for moving gas |
WO1997040783A2 (en) * | 1996-04-26 | 1997-11-06 | Jang G David | Intravascular stent |
US6241760B1 (en) * | 1996-04-26 | 2001-06-05 | G. David Jang | Intravascular stent |
US5807404A (en) * | 1996-09-19 | 1998-09-15 | Medinol Ltd. | Stent with variable features to optimize support and method of making such stent |
US5868781A (en) * | 1996-10-22 | 1999-02-09 | Scimed Life Systems, Inc. | Locking stent |
WO1998020810A1 (en) * | 1996-11-12 | 1998-05-22 | Medtronic, Inc. | Flexible, radially expansible luminal prostheses |
AU6464298A (en) * | 1997-03-13 | 1998-09-29 | United States Surgical Corporation | Flexible tissue supporting device |
US5913895A (en) * | 1997-06-02 | 1999-06-22 | Isostent, Inc. | Intravascular stent with enhanced rigidity strut members |
EP0884029B1 (en) * | 1997-06-13 | 2004-12-22 | Gary J. Becker | Expandable intraluminal endoprosthesis |
FR2764794B1 (en) * | 1997-06-20 | 1999-11-12 | Nycomed Lab Sa | EXPANDED TUBULAR DEVICE WITH VARIABLE THICKNESS |
US5824059A (en) * | 1997-08-05 | 1998-10-20 | Wijay; Bandula | Flexible stent |
US6342067B1 (en) * | 1998-01-09 | 2002-01-29 | Nitinol Development Corporation | Intravascular stent having curved bridges for connecting adjacent hoops |
US6019778A (en) * | 1998-03-13 | 2000-02-01 | Cordis Corporation | Delivery apparatus for a self-expanding stent |
US5911754A (en) * | 1998-07-24 | 1999-06-15 | Uni-Cath Inc. | Flexible stent with effective strut and connector patterns |
-
1998
- 1998-01-09 US US09/005,401 patent/US6129755A/en not_active Expired - Lifetime
-
1999
- 1999-01-04 CA CA002257751A patent/CA2257751C/en not_active Expired - Lifetime
- 1999-01-07 AU AU10065/99A patent/AU740593B2/en not_active Expired
- 1999-01-08 DE DE69915895T patent/DE69915895T2/en not_active Expired - Lifetime
- 1999-01-08 ES ES99300134T patent/ES2217689T3/en not_active Expired - Lifetime
- 1999-01-08 EP EP99300134A patent/EP0928605B1/en not_active Expired - Lifetime
- 1999-01-08 JP JP00346799A patent/JP4703798B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0928605A3 (en) | 2000-03-22 |
US6129755A (en) | 2000-10-10 |
ES2217689T3 (en) | 2004-11-01 |
EP0928605B1 (en) | 2004-03-31 |
AU740593B2 (en) | 2001-11-08 |
DE69915895D1 (en) | 2004-05-06 |
AU1006599A (en) | 1999-07-29 |
JPH11262531A (en) | 1999-09-28 |
EP0928605A2 (en) | 1999-07-14 |
DE69915895T2 (en) | 2005-03-24 |
JP4703798B2 (en) | 2011-06-15 |
CA2257751A1 (en) | 1999-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2257751C (en) | An intravascular stent having an improved strut configuration | |
US6342067B1 (en) | Intravascular stent having curved bridges for connecting adjacent hoops | |
US6190406B1 (en) | Intravascular stent having tapered struts | |
US6503271B2 (en) | Intravascular device with improved radiopacity | |
AU2002303157B2 (en) | Radiopaque intraluminal medical device | |
AU2015243099B2 (en) | Intraluminal device with improved flexibility and durability | |
EP2158880B1 (en) | Intravascular stent having improved design for loading and deploying | |
AU2002303157A1 (en) | Radiopaque intraluminal medical device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20190104 |